Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Department of Ophthalmology, Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for diabetic macular edema group:
- Diabetic macular edema with preoperative central macular thickness > 300 μm on optical coherence tomography
- Macular edema that was not associated with an epiretinal membrane or traction membrane
- No combined traction retinal detachment or vitreous hemorrhage
- No signs of ocular inflammatory disease on preoperative examination
- Phakic eye
- An axial length between 22.0 mm and 25.0 mm
Exclusion Criteria for diabetic macular edema group:
- Patients with uveitis, inflammatory connective tissue disorders or a history of previous ocular surgery
- Long-term application of topical medication, a history of intravitreal steroid or anti-VEGF injection within 3 months before vitrectomy
Inclusion Criteria for epiretinal membrane group:
- Non-diabetic patients with an epiretinal membrane who were scheduled for vitrectomy
- No ocular or systemic disease other than epiretinal membrane
Inclusion Criteria for healthy group:
- No diabetes
- No ocular disease other than cataract
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Diabetic Macular Edema Group
|
25-gauge three-port pars plana vitrectomy
|
|
Active Comparator: Epiretinal Membrane Group
|
25-gauge three-port pars plana vitrectomy
|
|
No Intervention: Healthy Control
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ciliary body thickness
Time Frame: up to four months after surgery
|
ciliary body thickness was determined using ultrasound biomicroscopy
|
up to four months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
central macular thickness
Time Frame: up to four months after surgery
|
central macular thickness was determined using optical coherence tomography
|
up to four months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Hyeong Gon Yu, M.D., Department of Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SNUH_OT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.